← boothcheck

Is EHC overvalued?

boothcheck doesn't label EHC overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, EHC is priced for growth of -3.5%. The price is supported by earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet. The more the price assumes beyond what Encompass Health Corporation has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from Encompass Health Corporation's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth-3.5%
For about
Margin needed
Margin today
Price vs asset value1.42x
Price vs earnings power1.14x
Price vs peer multiples0.79x
Price vs forward growth1.13x
Read the full EHC report →
Get boothcheck's read on what EHC's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.